Study of the effect of symbiotics on preventing ventilator- associated pneumonia

Study of the effect of symbiotics on preventing ventilator- associated pneumonia in children on mechanical ventilation

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220912055944N1

Enrollment

Registered

2023-05-04

Start date

2023-05-10

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Ventilator-associated pneumonia. Condition 2: Duration of mechanical ventilation. Condition 3: Duration of ICU stay. Condition 4: Duration of hospital stay. Condition 5: Mortality rate. Other acute lower respiratory infections

Interventions

Intervention 1: Intervention group: The patients who were put in this group prescribed KidiLact during the first 24 hour after intubation. This drug is produced by Zisttakhmir company and it includes

Eligibility

Sex/Gender

All

Age

1 Months to 9 Years

Inclusion criteria

Inclusion criteria: Children supported by mechanical ventilation for at least 48 hours and without primary immunodeficiency

Exclusion criteria

Exclusion criteria: Primary immunodeficiency

Design outcomes

Primary

Measure	Time frame
Percentage of patients who were infected with ventilator-associated pneumonia. Timepoint: At the beginning, middle and the end of the study. Method of measurement: Nonbronchoscopic bronchoalveolar lavage (NB-BAL).	—

Secondary

Measure	Time frame
Duration of ventilator-associated pneumonia treatment. Timepoint: Beginning and end of the treatment. Method of measurement: Number of the days that ventilator-associated pneumonia was treated.;Duration of mechanical ventilation. Timepoint: Beginning and end of the mechanical ventilation. Method of measurement: Number of the days the patients were under mechanical ventilation.;Duration of hospitalization in pediatric intensive care unit. Timepoint: Beginning and end of the hospitalization in pediatric intensive care unit. Method of measurement: Number of the days the patients were hospitalized in pediatric intensive care unit.;Duration of hospitalization. Timepoint: Beginning and end of the hospitalization. Method of measurement: Number of the days the patients were hospitalized.;Mortality rate. Timepoint: End of the study. Method of measurement: Counting the deaths.	—

Measure

Time frame

Duration of ventilator-associated pneumonia treatment. Timepoint: Beginning and end of the treatment. Method of measurement: Number of the days that ventilator-associated pneumonia was treated.;Duration of mechanical ventilation. Timepoint: Beginning and end of the mechanical ventilation. Method of measurement: Number of the days the patients were under mechanical ventilation.;Duration of hospitalization in pediatric intensive care unit. Timepoint: Beginning and end of the hospitalization in pediatric intensive care unit. Method of measurement: Number of the days the patients were hospitalized in pediatric intensive care unit.;Duration of hospitalization. Timepoint: Beginning and end of the hospitalization. Method of measurement: Number of the days the patients were hospitalized.;Mortality rate. Timepoint: End of the study. Method of measurement: Counting the deaths.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHanieh Basirkazeruni

Esfahan University of Medical Sciences

hany_med1384@yahoo.com+98 31 3666 4034

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026